On October 31, 2024, we will be updating our current Terms of Use and Privacy Notice. By continuing to use our products and service on October 31, 2024, you are agreeing to our updated Terms of Use and are acknowledging our updated Privacy Notice.
Tandem Diabetes Care’s symposium held during the 2022 ISPAD conference in Abu Dhabi (UAE) highlights the pediatric glycemic outcomes of the t:slim X2 insulin pump with Control-IQ technology. Dr. Marc Breton revealed the outcomes of the PEDAP randomized clinical trial in children ages 2-5. Dr. Amelie Poidvin reviewed the sustained glycemic control after 2 years of the school-aged FreeLife Kids cohort. And Dr. Laurel Messer reviewed the results of Control-IQ in the adolescent population.